{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:02:13Z","timestamp":1790017333655,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijrobp.2022.05.015","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T22:35:29Z","timestamp":1652999729000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hypofractionated Radiation Therapy Combined With Weekly Chemotherapy in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-Arm Phase 2 Study (GASTO-1042)"],"prefix":"10.1016","volume":"114","author":[{"given":"Chu","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-3756","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.05.015_bib0001","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the thymus: Continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0002","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/JTO.0b013e3181f1f62d","article-title":"Epidemiology of thymoma and associated malignancies","volume":"5","author":"Engels","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0003","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: A systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2003.09.022","article-title":"Multimodal management of stages III-IVa malignant thymoma","volume":"44","author":"Bretti","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0005","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ijrobp.2011.03.010","article-title":"Evaluation of the role of radiation therapy in the management of malignant thymoma","volume":"82","author":"Patel","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0006","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.athoracsur.2012.09.006","article-title":"Thymic carcinoma: A multivariate analysis of factors predictive of survival in 290 patients","volume":"95","author":"Weksler","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0007","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.29166","article-title":"Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus database study","volume":"121","author":"Omasa","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0008","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jtho.2019.10.018","article-title":"A recurrence predictive model for thymic tumors and its implication for postoperative management: A Chinese Alliance for Research in Thymomas database study","volume":"15","author":"Liu","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0009","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1038\/s41598-017-12909-z","article-title":"Prospective study of stereotactic body radiation therapy for thymoma and thymic carcinoma: Therapeutic effect and toxicity assessment","volume":"7","author":"Hao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0010","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2019.12.045","article-title":"Intensity modulated radiation therapy plus etoposide\/cisplatin for patients with limited advanced unresectable thymic epithelial tumors: A prospective phase 2 study","volume":"107","author":"Fan","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0012","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ijrobp.2020.09.058","article-title":"Intensity modulated radiation therapy for pleural recurrence of thymoma: A prospective phase 2 study","volume":"109","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0013","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated intensity modulated radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer: A phase II prospective clinical trial (GASTO1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0014","article-title":"Multicenter, randomized, phase III trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0015","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0016","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.21037\/jtd-2019-thym-10","article-title":"Autoimmune disorders and paraneoplastic syndromes in thymoma","volume":"12","author":"Blum","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0017","article-title":"Thymoma-associated T-cell immunodeficiency after radiotherapy: A case report","volume":"33","author":"Nakagawara","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0018","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0076-6879(85)16017-9","article-title":"Thymosin alpha 1 and polypeptide beta 1","volume":"116","author":"Low","year":"1985","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1415.045","article-title":"History of the discovery of the thymosins","volume":"1112","author":"Goldstein","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0020","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/cid\/ciaa630","article-title":"Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of lymphocytopenia and reversion of exhausted T cells","volume":"71","author":"Liu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0021","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12072-012-9386-z","article-title":"Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0022","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc11932","article-title":"The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial","volume":"17","author":"Wu","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0023","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2003-11-4036","article-title":"Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling","volume":"103","author":"Romani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0024","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.vh.2016.04.003","article-title":"Immune modulation with thymosin alpha 1 treatment","volume":"102","author":"King","year":"2016","journal-title":"Vitam Horm"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00199694","article-title":"Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays","volume":"15","author":"Umeda","year":"1983","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0026","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1759-7714.2011.00057.x","article-title":"Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Jiang","year":"2011","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0027","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.21037\/jtd.2017.08.133","article-title":"Chemoradiotherapy for unresectable cases of thymic epithelial tumors: A retrospective study","volume":"9","author":"Kashima","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0028","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cllc.2015.05.003","article-title":"A review of the place and role of radiotherapy in thymoma","volume":"16","author":"Lombe","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0029","doi-asserted-by":"crossref","first-page":"S2555","DOI":"10.21037\/jtd.2018.01.154","article-title":"The expanding role of radiation therapy for thymic malignancies","volume":"10","author":"Willmann","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0030","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1097\/JTO.0b013e3181f20ea2","article-title":"Technical advances of radiation therapy for thymic malignancies","volume":"5","author":"Gomez","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0031","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.ijrobp.2009.09.066","article-title":"Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection","volume":"78","author":"Chen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103244","article-title":"Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis","volume":"160","author":"Bongiovanni","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0033","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.30566","article-title":"Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials","volume":"123","author":"Kong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0034","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canrad.2019.09.009","article-title":"Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer","volume":"24","author":"Kaderbha\u00ef","year":"2020","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2021.11.033","article-title":"Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model","volume":"167","author":"Ai","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0036","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2019.03.035","article-title":"Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models","volume":"136","author":"Li","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0037","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10753-013-9753-5","article-title":"Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis","volume":"37","author":"Xiang","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0038","first-page":"139","article-title":"Effect of continuous blood purification and thymosin alpha 1 on the cellular immunity in patients with severe sepsis: A prospective, randomized, controlled clinical trial","volume":"21","author":"Li","year":"2009","journal-title":"Chinese Crit Care Med"},{"issue":"sup1","key":"10.1016\/j.ijrobp.2022.05.015_bib0039","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/14712598.2018.1484104","article-title":"Thymosin alpha 1 treatment for patients with sepsis","volume":"18","author":"Pei","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TA.0000000000000909","article-title":"Ulinastatin and\/or thymosin alpha 1 for severe sepsis: A systematic review and meta-analysis","volume":"80","author":"Feng","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0041","article-title":"Efficacy of thymosin alpha 1 in the treatment of COVID-19: A multicenter cohort study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: From biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0043","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1097\/JTO.0b013e3181f1f63f","article-title":"The autoimmune regulator AIRE in thymoma biology: Autoimmunity and beyond","volume":"5","author":"Marx","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0044","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/clim.1999.4710","article-title":"Correlation of thymic pathology with HLA in myasthenia gravis","volume":"91","author":"Machens","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ijrobp.2022.05.015_bib0045","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ijrobp.2022.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000}}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622004230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622004230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T21:30:53Z","timestamp":1679693453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622004230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0360301622004230"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated Radiation Therapy Combined With Weekly Chemotherapy in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-Arm Phase 2 Study (GASTO-1042)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}